The Metabolic Classroom with Dr. Ben Bikman

Episode: Ivermectin Explained: The Science Behind the Controversy

Date: March 23, 2026
Host: Dr. Ben Bikman, Metabolic Scientist
Summary by The Metabolic Classroom Summarizer

Episode Overview

This episode tackles the scientific story of ivermectin—a drug mired in political controversy since the pandemic. Dr. Ben Bikman focuses not on politics, but on the peer-reviewed science of ivermectin’s discovery, mechanisms, safety, and its underappreciated metabolic effects, particularly on mitochondria, cancer metabolism, inflammation, and insulin sensitivity. He challenges the surface-level "horse dewormer" narrative, unpacks its Nobel Prize-winning history, breaks down emerging research about its potential roles in cancer and metabolism, and calls for rigorous human studies.

Key Discussion Points & Insights

1. Origins and Humanitarian Impact of Ivermectin

• Discovery and Nobel Prize:
  • Isolated in 1975 from a Japanese soil bacterium (Streptomyces avermitilis); chemically modified to ivermectin.
  • Won the 2015 Nobel Prize in Physiology or Medicine for its transformative effects on human parasitic diseases—not for veterinary uses.
  • Used to control river blindness, lymphatic filariasis; reached 139 million people in a single 2014 WHO campaign.
• Rebutting “Horse Dewormer” Rhetoric:
  • Dismissal as a “horse dewormer” ignores its major impact on human health.
  • “Yes, Ivermectin is also used in veterinary medicine, but so is metformin, which is used in horses and dogs. So is aspirin.” (Ben Bikman, 04:54)
• Legal and Practical Access:
  • Increasing U.S. state-level access for human-grade (not veterinary) ivermectin over-the-counter; five states passed legislation by late 2025.

2. Classical Mechanism—Why It’s Safe in Humans

• Antiparasitic Action:
  • Binds glutamate-gated chloride channels in invertebrate parasites, leading to paralysis and death.
  • Humans lack these channels in the nervous system; blood-brain barrier further limits risk.
  • “The key reason this is relatively safe in mammals is that these specific glutamate gated chloride channels are essentially absent in our nervous system...” (Ben Bikman, 06:18)

3. Metabolic & Cellular Actions: Mitochondria and Cancer

• Inhibition of Mitochondrial Complex 1:
  • Ivermectin disrupts mitochondrial electron transport (complex 1), stalling ATP production.
  • Cancer cells, with high metabolic demand, are especially vulnerable to this disruption.
  • Research in glioblastoma, leukemia, renal, and other cancers shows selective toxicity.
  • Quote:
    • “When complex one is inhibited, ATP levels fall and the cells experience an energy crisis. This in turn activates AMPK... then MTOR is suppressed and the cancer cells are pushed toward growth arrest...” (Ben Bikman, 11:47)
• Triggering Apoptosis:
  • Loss of mitochondrial membrane potential leads to intrinsic apoptosis (programmed cell death), especially in cancer cells.
• Selectivity for Cancer Cells:
  • Studies found ivermectin affects tumor, but not normal cells, e.g., breast and kidney.

4. Additional Anti-Cancer Mechanisms

• PAK1 Inhibition:
  • Ivermectin promotes degradation of PAK1, a kinase overactive in the majority of human cancers; effect seen in breast, ovarian, melanoma, and nasopharyngeal cancer.
  • “In one well designed study, ivermectin had no significant effect on PAK1 levels in non tumorigenic breast cells, only in cancer cells.” (Ben Bikman, 15:59)
• Synergy with Chemotherapy:
  • In pancreatic cancer models, combination with gemcitabine showed greater cell death than chemo alone.

5. Anti-Inflammatory Effects

• NF-kappaB Suppression:
  • Blocks master inflammation regulator (NF-kappaB), lowering cytokine production and systemic inflammation; demonstrated in animal sepsis and asthma models.
  • May increase survival after inflammatory challenges (e.g., lethal LPS).
  • Direct connection: “Ivermectin blocks NF kappa B's ability... in turn reducing the downstream cytokine production and response.” (Ben Bikman, 17:42)
• AMPK and Metabolic Link:
  • AMPK activation (see earlier cancer/cell death pathway) also suppresses inflammation by inhibiting NF-kappaB, “connecting the dots” between metabolic, anti-cancer, and anti-inflammatory effects.

6. Effects on Insulin Resistance, Glucose Metabolism & Fat Cells

• FXR Activation:
  • Directly activates FXR (Farnesoid X Receptor), a bile acid nuclear receptor regulating glucose homeostasis and insulin sensitivity.
• Preclinical Study Results:
  • In rodent models:
    • Lower fasting glucose and insulin
    • Improved glucose tolerance and reduced blood pressure
    • Improved liver health (lower liver enzymes)
    • Inhibited formation of mature fat cells and reduced triglycerides in cultured fat cells via PPAR-gamma pathway
  • “Ivermectin has been shown to inhibit the differentiation of pre adipocytes into mature fat cells and to reduce the triglyceride accumulating in those fat cells.” (Ben Bikman, 22:41)
• Human Evidence:
  • Very preliminary: One small study in four type 2 diabetics noted improved HbA1c with daily ivermectin, but large controlled trials are lacking.
• Comparison to Metformin:
  • Mechanistically parallel in mitochondrial, anti-inflammatory, and insulin sensitivity roles; ivermectin is likened to “a different metformin.”

7. Safety Profile and Calls for More Research

• Established Safety:
  • Standard doses have benefitted hundreds of millions with an “excellent safety profile.”
  • WHO lists as an essential medicine; over-the-counter status expanding suggests “as safe as any other medication you would buy at any pharmacy.” (Ben Bikman, 26:55)
• Critique of Political Obstacles:
  • Barriers to research are political, not scientific. Historical examples (aspirin, metformin, rapamycin) show drugs can be successfully repurposed.
  • “When a compound has this much mechanistic rationale and history, the appropriate scientific response is to study it more rigorously in humans, not to dismiss it.” (Ben Bikman, 29:32)

Notable Quotes & Memorable Moments

On the "horse dewormer" narrative:

"When Ivermectin gets dismissed as just a horse dewormer, what we're really seeing, I think, is a rhetorical sleight of hand that strips away the drug's entire humanitarian history and Nobel Prize winning science..."
(Ben Bikman, 05:37)

On ivermectin’s multi-system effects:

“The metabolic effects of ivermectin, if they hold up in humans, are unlikely to be reducible to any single pathway. In other words, there's probably not one single reason… It's appears to be multifactorial.”
(Ben Bikman, 25:30)

On need for more research:

“The political controversy surrounding ivermectin may be creating barriers to the very clinical work that would resolve the uncertainty… The appropriate scientific response is to study it more rigorously in humans, not to dismiss it.”
(Ben Bikman, 29:32)

On his role and the episode’s aim:

“As always, my goal here is not to tell you what to do clinically. Remember, I'm not your clinician. I'm just your friendly neighborhood scientist... The science of Ivermectin deserves far more credit than it's been given, and I hope you feel like now you know why.”
(Ben Bikman, 31:50)

Important Timestamps

• [01:52] — Episode Intro and Theme
• [03:40] — Nobel Prize, Humanitarian Impact, and Reframing “Horse Dewormer” Label
• [06:15] — Classical Mechanism (Why it’s selectively toxic to parasites, not humans)
• [08:30] — Mitochondrial Effects and Anti-Cancer Mechanisms
• [11:47] — Mechanistic Cascade: Complex 1, AMPK, MTOR, Cancer Cell Death
• [15:59] — PAK1 Inhibition and Cancer Selectivity
• [17:42] — Suppression of NF-kappaB and Anti-Inflammatory Potential
• [19:20] — Ivermectin’s Effects on Insulin Resistance, Fat Accumulation
• [22:41] — Adipocyte Biology and Metabolic Syndrome
• [25:30] — Human Diabetes Data, Metformin Comparison, Multifactorial Mechanisms
• [26:55] — Safety Profile and Expanding Over-the-Counter Access
• [29:32] — Political Barriers, Research Needs, Drug Repurposing Examples
• [31:50] — Wrap-Up and Final Thoughts

Key Takeaways

• Ivermectin’s scientific story is far richer than recent public discourse suggests.
• Demonstrated anti-parasitic, anti-cancer, anti-inflammatory, and metabolic effects—with mechanistic parallels to leading diabetes drugs like metformin.
• Very strong safety record at standard human doses; preclinical evidence for broader roles is significant, but clinical trials are crucial.
• Political controversies should not obstruct scientific inquiry; ivermectin merits the same objective evaluation as other repurposed drugs.

End of Summary